Geron, BioTime Deal Moves Forward with Letter of Intent
By Dr. Matthew Watson
Geron Corp., which once pioneered human
embryonic stem cell research, is close to selling off its hESC business in a complicated deal involving two former CEOs of the company and
BioTime, Inc., of Alameda, Ca.
announced a “letter of intent” involving a transaction in which
BioTime would acquire the assets of Geron's hESC clinical trial that
the company suddenly abandoned last year. The firm also laid off 66 people,
about 40 percent of its staff.
few months after the $3 billion California stem cell agency loaned Geron $25 million to assist in the trial. The agency could
restore the loan for the trial, but the Geron-BioTime announcement
did not mention that possibility. The California Stem Cell Report has
asked the agency for comment.
one day after Geron announced that it was giving up the hESC spinal injury trial because of financial reasons. The Menlo Park, Ca., firm
has been trying to sell its hESC assets since then. BioTime has
been the only firm to express public interest. The Geron trial was
the first hESC trial approved by the FDA.
West, who founded Geron and is now head of Biotime, and Tom Okarma,
who was CEO of Geron from 1999 to 2011. Okarma is now head of BioTime
Acquisition Corp.,(BAC) a subsidiary of BioTime.
described the deal in which BioTime would acquire Geron's
“intellectual property and other assets related to Geron’s
discontinued human embryonic stem cell programs.”
“ BioTime would contribute
to BAC $5 million in cash, $30 million of BioTime common
shares, warrants to purchase eight (8) million common shares
of BioTime at a pre-specified price, rights to use certain
human embryonic stem cell lines, and minority stakes in two of
BioTime’s subsidiaries. In addition, a private investor would
invest $5 million in cash in BAC.
“Following consummation of the
potential transaction, Geron stockholders would receive
shares representing 21.4% of the common stock of BAC as well as
warrants to purchase 8 million shares of BioTime common
stock at a pre-specified price. BioTime would own
approximately 71.6%, and a private investor would own approximately
7.0% of the outstanding BAC common stock for their $5
million investment. BioTime would also receive
warrants that would enable it to increase its ownership in BAC by
approximately 2%, which would reduce the Geron stockholders’
ownership in BAC to 19.2%. BAC would also be committed to pay
to Geron royalties on the sale of products that are
commercialized in reliance upon Geron patents acquired by
BAC.”
intent, an article earlier this week by Vickie Brower in The Scientist said,
“The offer couldn’t come at a
better time for Geron, which in recent months has started to feel
pressure from its shareholders to boost its stock price and move
products through the pipeline. Since last November, when the company
announced its decision to shutter its hESC and regenerative medicine
business and funnel its resources into developing telomerase-related
treatments for cancer, the stock price has dropped more than 50
percent to $1.30 a share. Geron claimed the move was simply to save
money, but many took the decision—which effectively terminated a
clinical trial of an hESC treatment for spinal cord injury—as a
setback for the entire field."
News coverage of yesterday's
announcement was light. Here is a link to a piece by Ryan McBride on
Fierce Biotech.
yesterday and rose to $1.24 in after hours trading. BioTime closed at
$2.97. No after hours trading was reported for BioTime.
- Tracking the Fruits of California Stem Cell Agency Research - September 1st, 2013
- UCLA Snags $3.6 Million from California Stem Cell Agency - September 1st, 2013
- Stem Cell Agency Seeks Stronger Ties with Possible Industry Funding Partners - September 1st, 2013
- UCLA Takes Four of 13 Awards Today; One Business Wins - September 1st, 2013
- $41 Million in California Stem Cell Grants Virtually Approved - September 1st, 2013
- Stem Cell Agency Pays Tribute to the Late Duane Roth - September 1st, 2013
- Skin in California’s Stem Cell Game - September 1st, 2013
- California Stem Cell Agency's $150,000 Search for Its Financial Future - August 25th, 2013
- California Stem Cell Researchers to Receive $70 Million Next Week - August 25th, 2013
- Flim-Flam Stem Cell Artists Targeted by CIRM - August 25th, 2013
- California Stem Cell Agency Spending: Where the Money Is Going - August 25th, 2013
- A $2 Million Bill: Outside Contracting by California Stem Cell Agency - August 25th, 2013
- New Ties to Big Pharma and Venture Capital Proposed at California Stem Cell Agency - August 25th, 2013
- Bonilla: Veto of Pay-for-Eggs Bill Shows Troubling Mindset - August 18th, 2013
- 'Butter and Eggs Money" and a Gubernatorial Veto - August 18th, 2013
- California Gov. Jerry Brown Vetoes Pay-for-Eggs Legislation - August 18th, 2013
- A $6 Billion Question: Progress of the California Stem Cell Agency - August 18th, 2013
- Duane Roth: Ecumenical Innovator for San Diego and Biotech - August 18th, 2013
- Stem Cell Agency's Duane Roth Eulogized at Memorial Services - August 18th, 2013
- 'Paradigm Shift' -- Researchers as Patient Advocates? - August 18th, 2013
- California Stem Cell Agency on Lacks: Informed Consent Cannot Remove All Questions - August 11th, 2013
- Californians Top List of Stem Cell Honorees - August 11th, 2013
- The Henrietta Lacks Story and Eggs, Money and Motherhood - August 11th, 2013
- Skloots, Collins and More on Henrietta Lacks' Cell Line Deal - August 11th, 2013
- Memorial Services Friday for Duane Roth, Co-vice chairman of the California Stem Cell Agency - August 11th, 2013
- CIRM's Roth Dies Following Bike Accident - August 11th, 2013
- Pay-for-Eggs Legislation Now Before California Gov. Jerry Brown - August 4th, 2013
- Comment re Pay-for-Eggs Item and Forbes Article - August 4th, 2013
- Pay-for-Eggs Legislation: A Comment on Risk - August 4th, 2013
- Skimpy Coverage of Alpha Clinic Concept Approval - August 4th, 2013
- California Stem Cell Agency Looking for New Home in Two Years - August 4th, 2013
- California Stem Cell Official Duane Roth in Improving Condition - July 28th, 2013
- Another $23 Million to Recruit Star Stem Cell Scientists to California - July 28th, 2013
- California Stem Cell Agency Launches $70 Million Alpha Stem Cell Clinic Project - July 28th, 2013
- Coming Up: Live Coverage of Today's California Stem Cell Meeting - July 28th, 2013
- Stem Cell Lines and Paid-for Eggs: Stem Cell Agency Delays Action on Easing Restrictions - July 28th, 2013
- $70 Million Alpha Stem Cell Clinic Project Garners Mainstream Media Attention - July 28th, 2013
- UCLA Researcher Calls for Easing of Restrictions on Stem Cell Lines Derived from Eggs From Paid Providers - July 28th, 2013
- California Stem Cell Agency to Commit 20 Percent of Remaining Cash - July 21st, 2013
- Paying for Human Eggs, Ivan Illich and Jerry Brown - July 21st, 2013
- California's $70 Million 'Alpha' Stem Cell Clinic Plan Headed for Approval Next Week - July 21st, 2013
- TV News Piece on Pay-for-Eggs Airs in Los Angeles, San Francisco - July 14th, 2013
- Shestack Resignation Letter: Heartfelt and Eloquent - July 14th, 2013
- Veto Campaign Launched on California Pay-For-Eggs Bill - July 14th, 2013
- Sacramento Mental Health Advocate Appointed to Stem Cell Agency Board - July 14th, 2013
- California Stem Cell Merger: Capricor and Niles Therapeutics - July 14th, 2013
- Pay-for-Eggs Legislation: Strange Bedfellows and Existential Questions - July 14th, 2013
- "Comfort News" for California's Stem Cell Research Effort - July 14th, 2013
- HIV Clinical Trial Hailed by California Stem Cell Agency - July 14th, 2013
- Eggs and Cash: Stem Cell Agency Considering Easing Restrictions on Stem Cell Lines Derived Using Payments - July 14th, 2013
- California Legislation Removing Ban on Payments for Eggs for Research Heads to Governor - July 14th, 2013
- California Legislation, Human Egg Sales and Profits - July 7th, 2013
- Challenge to WARF hESC Patents Cites Recent U.S. Supreme Court Decision - July 7th, 2013
- Cost of a Stem Cell Therapy? An Estimated $512,000 - June 30th, 2013
- Bluebird and Banking: Media Pluses for California Stem Cell Agency - June 30th, 2013
- International team submits IND application - June 23rd, 2013
- Pay-For-Eggs Legislation Draws More Media Attention - June 23rd, 2013
- Compensation for Human Eggs Approved by Key California Senate Committee, But Not For CIRM Researchers - June 16th, 2013
- Merksamer Makes Only Bid For Stem Cell Agency Lobbying Contract - June 16th, 2013
- Cellular Dynamics: California Stem Cell Agency Recipient Plans $57 Million IPO - June 9th, 2013
- Light Coverage of Cellular Dynamics IPO But One Exec Says It's Good for Stem Cell Biz - June 9th, 2013
- Pomeroy on Doing the Right Thing and Foster Care - June 9th, 2013
- Vatican Funding for California Stem Cell Agency? - June 2nd, 2013
- Bluebird bio of Massachusetts Still Waiting for California Stem Cell Money - June 2nd, 2013
- California's Alpha Stem Cell Clinics: Open in 2014, Six to Eight Locations - June 2nd, 2013
- Monterey Newspaper Chides California Stem Cell Agency - June 2nd, 2013
- Trounson Proposes $70 Million, Fast-Track Stem Cell Clinic Plan for California - June 2nd, 2013
- $70 Million Alpha Stem Cell Clinic Proposal Draws Reader Comment - June 2nd, 2013
- Sacramento Bee: Ongoing Conflict Problems No Help for Future Funding of Stem Cell Agency - June 2nd, 2013
- Multimillion Dollar Carrots for Stem Cell Research in California - May 26th, 2013
- California Stem Cell Agency: 5 Percent Budget Increase for Coming Fiscal Year - May 26th, 2013
- $36 Million Recruitment: Names of Researchers Being Lured to California - May 26th, 2013
- Stem Cell Agency Approves $36 million to Recruit Six Scientists to California - May 26th, 2013
- California Stem Cell Agency to Court Patient Groups This Summer - May 26th, 2013
- Nature Reports on Lee Hood Conflict Case - May 26th, 2013
- Grant Reviewer Conflict in $40 Million Round at California Stem Cell Agency - May 26th, 2013
- Text of CIRM Comments on Lee Hood Questions - May 26th, 2013
- Replicating Oregon Cloning in California: Views on the Legality - May 19th, 2013
- Oregon-style Stem Cell Cloning Research Illegal in California: No Pay for Eggs in Golden State - May 19th, 2013
- Weissman Says Oregon-style Stem Cell Research Could be Done in California - May 19th, 2013